Skip to main content

Leon Francisco's Form 4 filing

Provention Bio, Inc. (PRVB) · filed Dec 27, 2022

Accession no.
0001493152-22-036596
Filed
Dec 27, 2022
Trade date
Dec 22-23, 2022
Filing delay
5 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $19.4K. It was filed 5 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Leon FranciscoCIK 0001728920Officer (Chief Scientific Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 22, 2022Common StockMOption exerciseAcquired+1,568$2.50+$3,9201,574,568Direct
Dec 22, 2022Common StockSSaleDisposed−1,568$10.00F1−$15,6801,573,000Direct
Dec 23, 2022Common StockMOption exerciseAcquired+375$2.50+$937.51,573,375Direct
Dec 23, 2022Common StockSSaleDisposed−375$10.00−$3,7501,573,000Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 22, 2022Common StockMOption exerciseDisposed−1,568$0.00$0540,152Direct
Dec 23, 2022Common StockMOption exerciseDisposed−375$0.00$0539,777Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.005 per share, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)